Clinical trials: RRMM
Multiple Myeloma Refractory, Multiple Myeloma Progression
Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM)
This is a prospective, single-arm, open-label, early exploratory clinical study designed to evaluate the safety, tolerability, and efficacy of the DQ1001 cell product in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT07622862
- Testing
- Allogeneic, off-the-shelf CAR-T cell injection targeting BCMA and GPRC5D
- Volunteers
- 16 people
- Sponsor
- Zhongshan Hospital (Xiamen), Fudan University
Relapsed or Refractory Multiple Myeloma
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
This phase II clinical trial design with a safety run-in period will be used to assess the rate of VGPR or better for the combination PVD-Dara in the treatment of RRMM.
- Trial name
- NCT05408026
- Testing
- Daratumumab, Pomalidomide
- Sponsor
- Alliance Foundation Trials, LLC.
Relapsed or Refractory Multiple Myeloma
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study is designed to evaluate the safety and tolerability of mRNA-2736 in participants with RRMM.
- Trial name
- NCT05918250
- Testing
- mRNA-2736
- Where
- 13 sites in United States, Canada
- Sponsor
- ModernaTX, Inc.
Multiple Myeloma
A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment
The purpose of the study (Part 1 and Part 2) is to evaluate the safety of a step-up dosing approach (starting with low doses followed by higher doses) of the study medicine (elranatamab) in participants with multiple myeloma that…
- Trial name
- MagnetisMM-9 (NCT05014412)
- Testing
- Elranatamab
- Where
- 50 sites in United States, Japan and 2 more
- Volunteers
- 86 people
- Sponsor
- Pfizer